Q3 2025 VolitionRX Ltd Earnings Call Transcript

Nov 14, 2025 / 01:30 PM GMT

Release Date Price: $6.62 (-6.60%)

Transcript 10-Q8-K

Key Points

Positve

VolitionRX Ltd (VNRX) signed two significant agreements this quarter: a research license and exclusive commercial option rights agreement with Werfin for antiphospholipid syndrome (APS) and a co-marketing and service agreement with Hologic.
Revenue for the third quarter grew by 32% compared to the same quarter last year, reaching $0.6 million.
Operating expenses decreased by 10% year-on-year and 18% for the first three quarters, reflecting strong cost management.
VolitionRX Ltd (VNRX) is making progress in the veterinary market with the validation of the I-10 analyzer for centralized labs, which could lead to increased revenue from wellness panels.
The company is actively engaged in discussions with around 10 leading diagnostic and liquid biopsy companies, indicating potential for future licensing deals.

Negative

Revenues remain unpredictable and lumpy at this early stage of commercialization, making it difficult to provide revenue guidance.
The company is still in the process of validating its products on clinical samples, which means revenue from new agreements has not yet been realized.
The milestone payment for feline cancer testing has been delayed due to challenges in finding cats with cancer for study completion.
The market for APS, while significant, is not one of the largest, with a total addressable market of approximately $85 to $90 million annually.
Despite cost reductions, the company continues to face a challenging market environment for raising capital, necessitating careful financial management.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VNRX.A - VolitionRX Ltd
Q3 2025 VolitionRX Ltd Earnings Call
Nov 14, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Volition RX Limited, 3rd quarter 2025 earnings conference call. During today's call, all parties will be in a listen-only mode. Following the presentation, the conference call will be open for questions. If you have a question, please press the star key followed by the number 1 on your touchstone phone. If you would like to withdraw your question, please press the star key followed by the number 2.

If you're using speaker equipment, please lift the handset before making your selections. This conference is being recorded today, November 14, 2025. I would now like to turn the conference over to Louise Batchelor, Group Chief Marketing and Communications Officer.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.